These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31349930)

  • 1. Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia.
    Vegas-Suarez S; Paredes-Rodriguez E; Aristieta A; Lafuente JV; Miguelez C; Ugedo L
    Int Rev Neurobiol; 2019; 146():259-279. PubMed ID: 31349930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
    Sellnow RC; Newman JH; Chambers N; West AR; Steece-Collier K; Sandoval IM; Benskey MJ; Bishop C; Manfredsson FP
    Acta Neuropathol Commun; 2019 Jan; 7(1):8. PubMed ID: 30646956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia.
    Dwi Wahyu I; Chiken S; Hasegawa T; Sano H; Nambu A
    J Neurosci; 2021 Mar; 41(12):2668-2683. PubMed ID: 33563724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers.
    Sgambato V; Tremblay L
    J Neural Transm (Vienna); 2018 Aug; 125(8):1145-1156. PubMed ID: 29502255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
    Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD
    Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
    Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
    Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM; Lee J; Venderova K
    J Neural Transm (Vienna); 2005 Mar; 112(3):359-91. PubMed ID: 15614429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.
    Obeso JA; Rodriguez-Oroz MC; Rodriguez M; DeLong MR; Olanow CW
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S22-32; discussion S32-4. PubMed ID: 10762129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic modulation of striatal function and Parkinson's disease.
    Zhai S; Shen W; Graves SM; Surmeier DJ
    J Neural Transm (Vienna); 2019 Apr; 126(4):411-422. PubMed ID: 30937538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.
    Del-Bel E; Padovan-Neto FE; Raisman-Vozari R; Lazzarini M
    Curr Pharm Des; 2011; 17(5):471-88. PubMed ID: 21375483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.
    Girasole AE; Lum MY; Nathaniel D; Bair-Marshall CJ; Guenthner CJ; Luo L; Kreitzer AC; Nelson AB
    Neuron; 2018 Feb; 97(4):787-795.e6. PubMed ID: 29398356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
    Calabresi P; Standaert DG
    Neurobiol Dis; 2019 Dec; 132():104579. PubMed ID: 31445160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S105-12; discussion S112-4. PubMed ID: 10762137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An implication of serotonergic fibers which goes beyond Levodopa-induced dyskinesia].
    Beaudoin-Gobert M; Tremblay L; Sgambato-Faure V
    Med Sci (Paris); 2015 Nov; 31(11):956-9. PubMed ID: 26576599
    [No Abstract]   [Full Text] [Related]  

  • 20. A quantitative study of levodopa-induced dyskinesia in Parkinson's disease.
    Caligiuri MP; Peterson S
    J Neural Transm Park Dis Dement Sect; 1993; 6(2):89-98. PubMed ID: 8117413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.